DE60234708D1 - Behandlung von sti571-resistenter oder -intoleranter chronischer myelogener leukemie mittels homoharringtonine alein oder in kombination mit anderen substanzen - Google Patents
Behandlung von sti571-resistenter oder -intoleranter chronischer myelogener leukemie mittels homoharringtonine alein oder in kombination mit anderen substanzenInfo
- Publication number
- DE60234708D1 DE60234708D1 DE60234708T DE60234708T DE60234708D1 DE 60234708 D1 DE60234708 D1 DE 60234708D1 DE 60234708 T DE60234708 T DE 60234708T DE 60234708 T DE60234708 T DE 60234708T DE 60234708 D1 DE60234708 D1 DE 60234708D1
- Authority
- DE
- Germany
- Prior art keywords
- treatment
- homogarringtonine
- intolerant
- substances
- alone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 title abstract 2
- 229960002411 imatinib Drugs 0.000 title abstract 2
- 230000001684 chronic effect Effects 0.000 title 1
- 208000032839 leukemia Diseases 0.000 title 1
- 239000000126 substance Substances 0.000 title 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 abstract 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 abstract 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 abstract 2
- 208000014767 Myeloproliferative disease Diseases 0.000 abstract 2
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 abstract 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 abstract 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 abstract 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 abstract 1
- HYFHYPWGAURHIV-UHFFFAOYSA-N homoharringtonine Natural products C1=C2CCN3CCCC43C=C(OC)C(OC(=O)C(O)(CCCC(C)(C)O)CC(=O)OC)C4C2=CC2=C1OCO2 HYFHYPWGAURHIV-UHFFFAOYSA-N 0.000 abstract 1
- HYFHYPWGAURHIV-JFIAXGOJSA-N omacetaxine mepesuccinate Chemical compound C1=C2CCN3CCC[C@]43C=C(OC)[C@@H](OC(=O)[C@@](O)(CCCC(C)(C)O)CC(=O)OC)[C@H]4C2=CC2=C1OCO2 HYFHYPWGAURHIV-JFIAXGOJSA-N 0.000 abstract 1
- 229960002230 omacetaxine mepesuccinate Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31696701P | 2001-09-05 | 2001-09-05 | |
| PCT/IB2002/003992 WO2003020252A2 (en) | 2001-09-05 | 2002-09-05 | Treatment of chronic myelogenous leukemia, resistant or intolerant to sti571, involving homoharringtonine alone or combined with other agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE60234708D1 true DE60234708D1 (de) | 2010-01-21 |
Family
ID=23231501
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60234708T Expired - Lifetime DE60234708D1 (de) | 2001-09-05 | 2002-09-05 | Behandlung von sti571-resistenter oder -intoleranter chronischer myelogener leukemie mittels homoharringtonine alein oder in kombination mit anderen substanzen |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US6987103B2 (enExample) |
| EP (2) | EP1443933B1 (enExample) |
| JP (2) | JP4794816B2 (enExample) |
| AT (2) | ATE451106T1 (enExample) |
| AU (1) | AU2002337410A1 (enExample) |
| CA (1) | CA2459822C (enExample) |
| CY (2) | CY1109799T1 (enExample) |
| DE (1) | DE60234708D1 (enExample) |
| DK (2) | DK1443933T3 (enExample) |
| ES (2) | ES2383771T3 (enExample) |
| PT (2) | PT1443933E (enExample) |
| WO (1) | WO2003020252A2 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6613753B2 (en) * | 2001-02-21 | 2003-09-02 | Supergen, Inc. | Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation |
| US6905669B2 (en) | 2001-04-24 | 2005-06-14 | Supergen, Inc. | Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase |
| US6998391B2 (en) * | 2002-02-07 | 2006-02-14 | Supergen.Inc. | Method for treating diseases associated with abnormal kinase activity |
| US20040192652A1 (en) * | 2002-12-06 | 2004-09-30 | Giles Francis J. | Pharmaceutical combinations and methods for the treatment of leukemia |
| US20050037992A1 (en) * | 2003-07-22 | 2005-02-17 | John Lyons | Composition and method for treating neurological disorders |
| US20050059682A1 (en) * | 2003-09-12 | 2005-03-17 | Supergen, Inc., A Delaware Corporation | Compositions and methods for treatment of cancer |
| US7250416B2 (en) * | 2005-03-11 | 2007-07-31 | Supergen, Inc. | Azacytosine analogs and derivatives |
| US7700567B2 (en) | 2005-09-29 | 2010-04-20 | Supergen, Inc. | Oligonucleotide analogues incorporating 5-aza-cytosine therein |
| US20070117776A1 (en) * | 2005-11-04 | 2007-05-24 | John Lyons | Low Dose Therapy Of DNA Methylation Inhibitors |
| BRPI0710496A2 (pt) * | 2006-04-07 | 2011-08-16 | Novartis Ag | combinação que compreende a) composto de pirimidilaminobenzamida e b) inibidor de thr315iie cinase |
| EP2049096A4 (en) * | 2006-08-02 | 2012-05-09 | Univ South Florida | METHOD FOR TREATING CHRONIC MYELOGENIC LEUKEMIA CELLS |
| AU2008240044B2 (en) * | 2007-04-13 | 2013-09-12 | Teva Pharamceuticals International Gmbh | Oral cephalotaxine dosage forms |
| EP2229160A1 (en) * | 2007-12-07 | 2010-09-22 | ChemGenex Pharmaceuticals, Inc. | Leukemic stem cell ablation |
| JP5617175B2 (ja) | 2008-04-17 | 2014-11-05 | 富士電機株式会社 | ワイドバンドギャップ半導体装置とその製造方法 |
| CN103619168B (zh) * | 2011-06-29 | 2015-09-23 | 宾州研究基金会 | 用于治疗白血病的组合物、方法和药盒 |
| HUE042327T2 (hu) | 2011-08-30 | 2019-06-28 | Astex Pharmaceuticals Inc | Decitabin-származék készítmények |
| WO2017004538A1 (en) | 2015-07-02 | 2017-01-05 | Otsuka Pharmaceutical Co., Ltd. | Lyophilized pharmaceutical compositions |
| BR112020002280A2 (pt) | 2017-08-03 | 2020-07-28 | Otsuka Pharmaceutical Co., Ltd. | composto farmacológico e métodos purificação do mesmo |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030148955A1 (en) * | 1999-04-19 | 2003-08-07 | Pluenneke John D. | Soluble tumor necrosis factor receptor treatment of medical disorders |
-
2002
- 2002-09-05 DE DE60234708T patent/DE60234708D1/de not_active Expired - Lifetime
- 2002-09-05 WO PCT/IB2002/003992 patent/WO2003020252A2/en not_active Ceased
- 2002-09-05 PT PT02772653T patent/PT1443933E/pt unknown
- 2002-09-05 EP EP02772653A patent/EP1443933B1/en not_active Expired - Lifetime
- 2002-09-05 DK DK02772653.8T patent/DK1443933T3/da active
- 2002-09-05 AU AU2002337410A patent/AU2002337410A1/en not_active Abandoned
- 2002-09-05 AT AT02772653T patent/ATE451106T1/de active
- 2002-09-05 AT AT09172828T patent/ATE548041T1/de active
- 2002-09-05 ES ES09172828T patent/ES2383771T3/es not_active Expired - Lifetime
- 2002-09-05 DK DK09172828.7T patent/DK2177223T3/da active
- 2002-09-05 ES ES02772653T patent/ES2334774T3/es not_active Expired - Lifetime
- 2002-09-05 PT PT09172828T patent/PT2177223E/pt unknown
- 2002-09-05 CA CA2459822A patent/CA2459822C/en not_active Expired - Fee Related
- 2002-09-05 JP JP2003524561A patent/JP4794816B2/ja not_active Expired - Fee Related
- 2002-09-05 EP EP20090172828 patent/EP2177223B9/en not_active Expired - Lifetime
-
2003
- 2003-03-27 US US10/397,267 patent/US6987103B2/en active Active
-
2009
- 2009-02-02 JP JP2009021692A patent/JP2009102408A/ja active Pending
-
2010
- 2010-02-10 CY CY20101100126T patent/CY1109799T1/el unknown
-
2012
- 2012-06-06 CY CY20121100501T patent/CY1112817T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HK1067562A1 (en) | 2005-04-15 |
| US6987103B2 (en) | 2006-01-17 |
| EP2177223A3 (en) | 2010-05-19 |
| DK1443933T3 (da) | 2010-01-25 |
| HK1143732A1 (en) | 2011-01-14 |
| PT1443933E (pt) | 2010-01-27 |
| WO2003020252A2 (en) | 2003-03-13 |
| EP1443933A2 (en) | 2004-08-11 |
| EP1443933B1 (en) | 2009-12-09 |
| CY1109799T1 (el) | 2014-09-10 |
| EP2177223B9 (en) | 2012-10-31 |
| CA2459822C (en) | 2013-01-29 |
| CY1112817T1 (el) | 2016-02-10 |
| DK2177223T3 (da) | 2012-04-10 |
| PT2177223E (pt) | 2012-05-23 |
| JP2009102408A (ja) | 2009-05-14 |
| AU2002337410A1 (en) | 2003-03-18 |
| CA2459822A1 (en) | 2003-03-13 |
| EP2177223B1 (en) | 2012-03-07 |
| ES2334774T3 (es) | 2010-03-16 |
| EP2177223A2 (en) | 2010-04-21 |
| ATE548041T1 (de) | 2012-03-15 |
| US20040019036A1 (en) | 2004-01-29 |
| ES2383771T3 (es) | 2012-06-26 |
| JP4794816B2 (ja) | 2011-10-19 |
| WO2003020252A3 (en) | 2003-06-19 |
| ATE451106T1 (de) | 2009-12-15 |
| JP2005508896A (ja) | 2005-04-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1112817T1 (el) | Ομοχαρριγκτονινη μονη ή συνδυασμενη με αλλους παραγοντες για χρηση στην αγωγη της χρονιας μυελογενους λευχαιμιας, ανθεκτικης ή μη ανεκτικης σε αναστολεις πρωτεϊνικης κινασης εκτος του sτi 571 | |
| DK1503788T3 (da) | Behandling af alpha-galactosidase A-deficiens | |
| DE60042598D1 (de) | Medikamente zur behandlung des syndroms der chronishen ermüdung, das mit fibromyalgie und reizdarm assoziert ist. | |
| ATE399553T1 (de) | Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen | |
| ATE555803T1 (de) | Verwendung von osteopontin zur behandlung und/oder vorbeugung von neurologischen erkrankungen | |
| DE60115872D1 (de) | Cabergolin zur behandlung von fibromyalgie und chronic-fatigue-syndrom | |
| AR045870A1 (es) | Terapia de combinacion para la infeccion de virus de hepatitis c | |
| DE602004011051D1 (de) | Verfahren zur behandlung von krankheiten mit hsp90-hemmenden mitteln in kombination mit antimetaboliten | |
| DE602004022285D1 (de) | Verfahren zur behandlung von erkrankungen mit hsp90-hemmenden mitteln in kombination mit antimitotika | |
| DE602004017283D1 (de) | Verfahren zur behandlung von schwerer herzinsuffizienz und medikament dafür | |
| DE69833645D1 (de) | Neue therapeutische kombinationen aus mirtazapin und antipsychotika, zur behandlung oder prophylaxe von psychotischen störungen | |
| DE60304695D1 (de) | 7-ARYLSULFONAMID-2,3,4,5-TETRAHYDRO-1H-BENZOiDöAZEPINE MIT 5-HT6 REZEPTOR AFFINITÄT ZUR BEHANDLUNG VON ZENTRALNERVENSYSTEMERKRANKUNGEN | |
| ATE356994T1 (de) | Screeningverfahren mit pim1-kinase oder pim3- kinase | |
| ATE356995T1 (de) | Verfahren zur identifizierung von mitteln zur behandlung von diabetes | |
| DE602004004883D1 (de) | Vegf-antagonisten zur behandlung von diabetes | |
| DE60128009D1 (de) | Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma | |
| DE602004016126D1 (de) | Aplidine zur behandlung von multiplem myelom | |
| ATE356553T1 (de) | Futterzusatzmittel | |
| ATE269085T1 (de) | Verwendung von diltiazem zur behandlung von pathologien der netzhaut | |
| DE60206280D1 (de) | Verwendung von extrakten aus ginkgo biloba zur herstellung eines medikaments zur behandlung von sarcopenia | |
| DE602006015373D1 (de) | Zusammensetzungen und Verfahren zur Prävention und Behandlung von immunvermittelten Entzündungskrankheiten | |
| ATE545423T1 (de) | Mittel zur behandlung von lungenkrebs | |
| ATE486612T1 (de) | Verfahren zur behandlung von diabetes typ 2 | |
| DE602006020838D1 (de) | Medikamente zur prävention oder behandlung von herzversagen mit einem anticholinergikum | |
| ATE291425T1 (de) | R-eliprodil zur behandlung von glaucoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |